Janssen says Rybrevant combination study showed 30% risk reduction

Johnson & Johnson’s Janssen Pharmaceutical announced results from the Phase 3 MARIPOSA study showing Rybrevant in combination with lazertinib compared to osimertinib resulted in a 30% reduction in the risk of disease progression or death in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with either epidermal growth factor receptor exon 19 deletions or L858R substitution Results also showed a favorable trend in overall survival for Rybrevant and lazertinib in these patients compared to osimertinib at a first interim analysis, Janssen said in a statement. At a median follow-up of 22 months, median progression-free survival for Rybrevant lazertinib was 23.7 months compared to 16.6 months for osimertinib.